Invitae, which specializes in genetic information, has expanded its neurology and cardiology test offerings by adding 11 new panels for genetic diseases. The company has also updated 17 of its neurology panels and eight of its cardiology panels based on recent discoveries in the field of genetics, including tests for muscular dystrophies.
With this expansion, Invitae will be able to provide quality information on genetic changes proven to affect a series of neurologic and cardiovascular disorders, with the results coming in the same three-week period as previously, the company said in a press release.
The new panels are available immediately for use at children’s hospitals, and by pediatricians and medical genetics professionals, for diagnosis and care.
Invitae’s areas of genetic testing now include:
- Hereditary Parkinson’s Disease & Parkinsonism Panel
- Comprehensive Neuropathies Panel
- Comprehensive Neuromuscular Disorders Panel, with 116 genes covering muscular dystrophy, myopathy, and congenital myasthenic syndrome
- Additional myopathy panels
- Additional neuropathy panels
Furthermore, updates to existing panels included:
- A comprehensive CMT panel, now with 45 genes
- A comprehensive hereditary spastic paraplegia (HSP) panel, now with 63 genes
- The Cardiomyopathy and Skeletal Muscle Disease Panel, an option for patients with overlapping features associated with cardiomyopathies and muscular dystrophies (MD), which tend to require multiple test orders
Prices do not differ regardless of how many genes are required to be analyzed for an accurate diagnosis. For payers and institutions in contact with Invitae, prices can start at $950, depending on the requirements. For third-party payers, outside of Invitae’s network, prices per clinical area start at $1,500. For patients who do not have third-party insurance coverage or who do not meet insurance criteria for coverage, Invitae’s offers full tests at $475 per clinical area.
“Invitae is steadfast in its commitment to making high-quality genetic tests based on the latest clinical and scientific evidence available to patients and their family members,” Robert Nussbaum, M.D., Invitae’s chief medical officer, said in the release. “The launch of our new and updated panels clearly illustrates our ongoing dedication to careful and comprehensive gene curation.”